• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
Health

Israeli health ministry says Pfizer vaccine prevents severe sickness—but not infection

By
Yaacov Benmeleh
Yaacov Benmeleh
and
Bloomberg
Bloomberg
Down Arrow Button Icon
By
Yaacov Benmeleh
Yaacov Benmeleh
and
Bloomberg
Bloomberg
Down Arrow Button Icon
July 23, 2021, 4:47 AM ET
Video Poster

Pfizer Inc.’s Covid-19 vaccine provided a strong shield against hospitalization and more severe disease in cases caused by the contagious delta variant in Israel in recent weeks, even though it was just 39% effective in preventing infections, according to the country’s health ministry.

The vaccine, developed with BioNTech SE, provided 88% protection against hospitalization and 91% against severe illness for an unspecified number of people studied between June 20 and July 17, according to a report Thursday from the health ministry.

The report said that the data could be skewed because of different ways of testing vaccinated groups of people versus those who hadn’t been inoculated. Still, the data are likely to fuel debate over whether booster shots should be given to people who’ve already been vaccinated — something Pfizer has said it plans to request in the U.S. Israeli authorities said earlier this month they’ll only give a third round of shots to people with weakened immune systems.

The data out of Israel, which had earlier access to vaccines than most anywhere else in the world, contrast with a study out of the U.K. That paper, published this week in the New England Journal of Medicine, found that two doses of the Pfizer-BioNTech vaccine offer 88% protection against symptomatic disease caused by the delta variant and 94% against the alpha variant that was first discovered in Britain. Public Health England also previously found that the Pfizer and BioNTech shot was 96% effective against hospitalization.

Pfizer and BioNTech are confident in the protection and safety of the two-dose vaccine, Pfizer said in a statement on Friday. BioNTech is conducting an ongoing review of study data on the vaccine, a spokeswoman said.

Analysis of the companies’ more than 43,000-person clinical trial shows that effectiveness against symptomatic infection dips over time, from 95% in the first two months to the low- to mid-80% range four to six months after the second dose, Pfizer said.

The delta variant first emerged in India and is spreading around the globe as governments race to inoculate people, sometimes infecting those already fully vaccinated against Covid. The mutation has forced some countries to delay or rethink plans to loosen curbs on businesses, activity and travel.

Israel has had one of the world’s most effective inoculation drives, with 57% of the population fully vaccinated, but has seen a recent surge in infections due to delta. Critical cases have also climbed, but remain a fraction of the peak earlier this year.

Prime Minister Naftali Bennett has urged vaccine holdouts — who number some 1.1 million people — to get inoculated, calling it the most effective way to defeat the delta strain. The government has also reinstated some restrictions for indoor events and plans to ban flights to several countries with rising infection rates, including the U.K. and Cyprus.

–With assistance from Naomi Kresge.

Subscribe to Fortune Daily to get essential business stories straight to your inbox each morning.

About the Authors
By Yaacov Benmeleh
See full bioRight Arrow Button Icon
By Bloomberg
See full bioRight Arrow Button Icon

Latest in Health

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025

Most Popular

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • World's Most Admired Companies
  • See All Rankings
  • Lists Calendar
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

Latest in Health

Simple App Review (2026): Expert Tested and Reviewed
Healthmeal delivery
Simple App Review (2026): Expert Tested and Reviewed
By Emily PharesApril 30, 2026
4 hours ago
Premium card perks are ‘designed to create a win-win-win for everyone’ but customers are paying with heavy annual fees and data
Personal FinancePersonal Finance Evergreen
Premium card perks are ‘designed to create a win-win-win for everyone’ but customers are paying with heavy annual fees and data
By Catherina GioinoApril 30, 2026
5 hours ago
hoskins
Commentaryoffices
Gensler Co-Chair: Hot-desking was supposed to save money. It may be costing you your culture
By Diane HoskinsApril 30, 2026
11 hours ago
raw milk
Politicsmilk
Risk of paralysis, bacteria, even death is no match for Americans’ thirst for raw milk
By Laura Ungar, Jonel Aleccia and The Associated PressApril 29, 2026
1 day ago
The Best Protein Shakes of 2026: Tasted and Approved by Nutrition Experts
HealthDietary Supplements
The Best Protein Shakes of 2026: Tasted and Approved by Nutrition Experts
By Christina SnyderApril 29, 2026
1 day ago
aging
HealthLongevity
We’re the CEOs of Peloton and the Hospital for Special Surgery. Living longer isn’t enough, we need to live better, too
By Bryan T. Kelly and Peter SternApril 29, 2026
1 day ago

Most Popular

Apple cofounder Ronald Wayne—whose stake would be worth up to $400 billion had he not sold it in 1976—says that at 91, he has no regrets
Success
Apple cofounder Ronald Wayne—whose stake would be worth up to $400 billion had he not sold it in 1976—says that at 91, he has no regrets
By Preston ForeApril 27, 2026
3 days ago
Google Cloud revenue is now 18% of Alphabet's business. Is this the beginning of the end of Google's search identity?
Big Tech
Google Cloud revenue is now 18% of Alphabet's business. Is this the beginning of the end of Google's search identity?
By Alexei OreskovicApril 29, 2026
20 hours ago
‘They left me no choice’: Powell isn’t going anywhere—blocking Trump from another Fed appointee
Banking
‘They left me no choice’: Powell isn’t going anywhere—blocking Trump from another Fed appointee
By Eva RoytburgApril 29, 2026
1 day ago
Jamie Dimon gets candid about national debt: ‘There will be a bond crisis, and then we’ll have to deal with it’
Economy
Jamie Dimon gets candid about national debt: ‘There will be a bond crisis, and then we’ll have to deal with it’
By Eleanor PringleApril 29, 2026
1 day ago
‘The cost of compute is far beyond the costs of the employees’: Nvidia executive says right now AI is more expensive than paying human workers
AI
‘The cost of compute is far beyond the costs of the employees’: Nvidia executive says right now AI is more expensive than paying human workers
By Sasha RogelbergApril 28, 2026
3 days ago
With no end in sight, Trump considers new options in Iran war—including the ‘Dark Eagle’ hypersonic missile
Big Tech
With no end in sight, Trump considers new options in Iran war—including the ‘Dark Eagle’ hypersonic missile
By Jim EdwardsApril 30, 2026
12 hours ago

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.